ReviewCardiovascular toxicology2022
Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.
Review in Cardiovascular toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 241 citations in OpenAlex.
- Cardiorenal Associations in Preclinical Modeling: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Recent advances in application of hydrogel-based nanomaterials in breast cancer: from drug delivery, immunotherapy mechanisms to clinical applications.Journal of nanobiotechnology · 2026Pooled it
- Effects of Physical Exercise and the use of Doxorubicin on Cardiac Function in Rodents: A Systematic Review and Meta-Analysis.Current cardiology reviews · 2025Pooled it
- The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study.Drug safety · 2023Trial
- Article
- Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma.European journal of haematology · 2026Article
- Cardiovascular Organoids With Adjustable Endothelial Composition via SOX17-Engineered hPSCs.Biotechnology and bioengineering · 2026Article
- Dexpanthenol Attenuates Doxorubicin-Induced Cardiotoxicity by Modulating Oxidative Stress, Inflammation, and Apoptosis.Cardiovascular toxicology · 2026Article
- Babao Dan Improves Doxorubicin-Induced Cardiomyopathy by Activating Nrf2/GPX4 Signaling Pathway.Chinese journal of integrative medicine · 2026Article
- Beyond β-Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology.Kinases and phosphatases · 2026Article
- Urolithin A mitigates doxorubicin-induced myocardial injury via suppression of ROS-driven apoptotic signaling.Histology and histopathology · 2026Article
- Mesoporous-Shell Monolayer Plasmonic Architecture Enables Quantitative and Decision-Guided SERS.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanisms of Doxorubicin-Induced Cardiac Senescence and Potential Therapeutic Strategies.Biomolecules · 2026Review
- Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats.International journal of molecular sciences · 2026Article
- Engineering a bi-functional nanoplatform containing FH peptide for preferential cardiac delivery to counteract doxorubicin-induced cardiotoxicity.Journal of translational medicine · 2026Article
- A peptide-based screen for cell death inhibitors identifies the cytoprotective compound CDL36.bioRxiv : the preprint server for biology · 2026Article
- Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy.Advanced healthcare materials · 2026Article
- Allicin-loaded soluplus polymeric micelles differentially modulate doxorubicin response in adenocarcinoma and myocardial cell models.Scientific reports · 2026Article
- Apelin-13 attenuates doxorubicin-induced myocardial injury via the PI3K/AKT and ERK/MAPK signaling pathways.Cardiovascular diagnosis and therapy · 2026Article
- Class Effect of SGLT2 Inhibitors Against Doxorubicin-Induced Cardiotoxicity via Regulating Adenosine Kinase Mediated-Cardiac Oxidative Stress.Cardiovascular drugs and therapy · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin is an effective chemotherapeutic agent prescribed to treat solid tumors (e.g., ovary, breast, and gastrointestinal cancers). This anti-cancer drug has various side effects, such as allergic reactions, cardiac damage, hair loss, bone marrow suppression, vomiting, and bladder irritation. The most dangerous side effect of doxorubicin is cardiomyopathy, leading to congestive heart failure. The exact mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood. Alteration in myocardial structure and functional cardiac disorders is provoked by doxorubicin administration; subsequently, cardiomyopathy and congestive heart failure can occur. Congestive heart failure due to doxorubicin is associated with mortality and morbidity. Probably, doxorubicin-induced cardiotoxicity starts from myocardial cell injury and is followed by left ventricular dysfunction. Many factors and multiple pathways are responsible for the creation of doxorubicin-induced cardiotoxicity. Inflammatory cytokines, oxidative stress pathways, mitochondrial damage, intracellular Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.